Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1996-05-22
2000-08-15
Adams, Donald E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
4241881, 4242321, A61K 3912, A61K 3921, A61K 39275
Patent
active
061032441
ABSTRACT:
A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described. Also disclosed are novel poxvirus vectors for direct molecular cloning of open reading frames into a restriction enzyme cleavage site that is unique in the vector. In one model poxvirus vector, the open reading frame is transcribed by a promoter located in the vector DNA upstream of a multiple cloning site comprised of several unique cleavage sites.
REFERENCES:
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5155020 (1992-10-01), Paoletti
patent: 5174993 (1992-12-01), Paoletti
patent: 5204243 (1993-04-01), Paoletti
patent: 5225336 (1993-07-01), Paoletti
patent: 5338683 (1994-08-01), Paoletti
patent: 5364773 (1994-11-01), Paoletti et al.
patent: 5453364 (1995-09-01), Paoletti
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5505941 (1996-04-01), Paoletti
patent: 5583028 (1996-12-01), Paoletti et al.
Moss, B., "Poxviridae and their replication", in Virology, Second Edition, Fields et al., eds., Raven Press Ltd., New York, 1990, pp. 2079-2081.
Moss, B., in "Poxviridae: The Viruses and Their Replication", in Virology, Third Edition, Fields et al., eds., Lippincott-Raven Publishers, Philadelphia, 1996, pp. 2637-2639.
Coffin, J., in "Retroviridae and their replication" in Virology, Second Edition, Fields et al., eds., Raven Press Ltd., New York, 1990, pp. 1437-1440.
Spehner et al., 1990, J. Virol. 64(2):527-533.
Hu et al., 1990, Virol. 179:321-329.
Hu et al., 1987, Nature 328:721-723.
Baxby et al. "Vaccinia Virus," Vaccinia Viruses as Vectors for Vaccine Antigens Quinnan, Ed., Elsevier NY pp. 3-8 (1985).
Henderson et al. "Utilization of Vaccine in the Global Eradication of Smallpox," Vaccinia Viruses as Vectors for Vaccine Antigens Quinnan, Ed., Elsevier NYpp. 61-67 (1985).
Haber et al. "Innovative Approaches to Plasminogeen Activator Therapy," Science 243:51-56 (1989).
Weir et al. "Maping of the Vaccinia Virus Thymidine Kinase Gene by Marker Rescue and by Cell-Free Translation of Selected mRNA," P.N.A.S. 79:1210-1214 (1982).
Smith et al. "Construction and Characterization of an infectious Vaccinia Virus Recombinant that Expresses the Influenza Hamagglutinin Gene and Induces resistance to Influenza Virus Infection in Hamsters," P.N.A.S. 80:7155-7159 (1983).
Smith et al. "Infectious Vaccinia Virus Recombinants that Express Hepatitis B Surface Antigen," Nature 302:490-495 (1983).
Buller et al. "Decreased Virulence of Recombinant Vaccinia Virus Expression Vectors is Associated with a Thymidine Kinase-Negative Phenotype," Nature 317:813-815 (1985).
Buller et al. "Deletion of the Vaccinia Virus Growth Factor Gene Reduces Virus Virulence," Journal of Virology 62:866-874 (1988).
Flexner et al. "Prevention of Vaccinia Virus Infection in Immunodeficient Mice by Vector-Directed IL-2 Expression," Nature 330:259-262 (1987).
Shida et al. "Effects and Virulences of Recombinant Vaccinia Viruses Derived from Attenuated Strains that Express the Human T-Cell Leukemia Virus ZType I Envelope Gene," Journal of Virology 62:4474-4480 (1988).
Kotwal et al. "Mapping and Insertional Mutagenesis of a Vaccinia Virus Gene Encoding a 13,800-Da Secreted Protein," Virology 171:579-587 (1989).
Child et al. "Insertional Inactivation of the Large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus is Associated with Reduced Virulence in Vivo," Virology 174:625-629 (1990).
Taylor et al. Virology 6:497--(1988).
Moss et al. "Vaccinia Virus: A Tool for Research and Vaccine Development," Science 252:1662-1667 (1991).
Cooney et al. "Safety of and Immunological Response to a Recombinant Vaccinia Virus Vaccine Expressing HIV Envelope Glycoprotein," Lancet 337:567-572 (1991).
Sam & Dumbell Ann. Virol. 132E:135 (1981).
Panicali et al. P.N.A.S. 79:4927-4931 (1982).
Mackett et al. P.N.A.S. 79:7415-7419 (1982).
Miner et al. TIBTECH 8:20-25 (1990).
Fenner et al. The Poxviruses 12:355-356 (Academic Press, NY) (1989).
Mackett et al. Journal of General Virology 67:2067-2082 (1986).
Moss et al. Annual Review of Immunology 5:305-324 (1987).
Gritz et al. Journal of Virology 64:5948-5957 (1990).
Hruby et al. P.N.A.S. 88:3190-3194 (1991).
Harley et al. Arch. Virol. 113:133-141 (1990).
Panicali et al. Journal of Virology 37:1000-1010 (1981).
Goebel et al. Virology 179:246-266 (1990).
Ghildy et al. Arch. Virol. 106:85-92 (1989).
Schnitzlein et al. Virus Research 10:65-76 (1988).
Fenner et al. Virology 11:185-201 (1960).
Boyle et al. Research in Virology 140:483-491 (1989).
Bestock et al. Vet. Microbiol. 23:55-71 (abstract only) (1990).
Chakrabarti et al. Molec. Cell. Biol. 5:3403-3409 (1985).
Spehner et al. Journal of Virology 64:527-533 (1990).
Boursnell et al. Journal of General Virology 71:621-628 (1990).
Burke et al. Genet. Anal. Tech. Appl. 7:54-99 (1990).
Steinberg et al. Genet. Anal. Tech. Appl. 7:126-132 (1990).
Rixon et al. Journal of General Virology 71:2931-2939 (1990).
Langridge et al. J. Invert. Pathol. 42:77-82 (1983).
Scheiflinger et al. P.N.A.S. 89:9977-9981 (1992).
Merchlinsky et al. Virology 190:522-526 (1992).
Fenner et al. The Orthopoxviruses pp. 29-60 (1989) (Academic Press, NY).
Altenburger et al. Archives of Virology 105:15-27 (1989).
Barrett Et Al. Aids Research and Human Retroviruses 5(2): 159-171 (1989).
Boshart Et Al. Cell 41: 521-530 (1985).
Broyles Et Al. Journal of Biological Chemistry 263(22): 10754-10765 (1988).
Broyles Et Al. Journal of Virology 67(9): 5677-5680 (1993).
Condit Et Al. Virology 128: 429-443 (1983).
Gunning Et Al. Proc. Natl. Acad. Sci. USA 84: 4831-4835 (1987).
Hunt Et Al. Proc. Natl. Acac. Sci. USA 82:6455-6459 (1985).
Isaacs Et Al. Virology 178: 626-630 (1990).
Kane Et Al. Jounal of Virology 67(5): 2689-2698 (1993).
Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, pp. 47-56.
Mann Et Al. Cell 33: 153-159 (1983).
Taylor Et Al. Vaccine 6: 466-468 (1988).
Jindal Et Al. Journal of Virology 66(9): 5357-5362 (1992).
Fenner Et Al. The Orthopoxvirus, Chapter 12, pp. 353-377 (1988).
Falkner Et Al. Journal of Virology 64(6): 3108-3111 (1990).
Falkner Et Al. Journal of Virology 62(6): 1849-1854 (1988).
Gershon Et Al. Proc. Natl. Acad. Sci. USA 87: 4401-4405 (1990).
Graham Et Al. Virology 54: 536-539 (1973).
Wittek Et Al. Journal of Virology 49(2): 371-378 (1984).
Weir Et Al. Journal of Virology 56(2): 534-540 (1985).
Lai Et Al. Journal of Biological Chemistry 265(36): 22174-22180 (1990).
Zhang Et Al. Virology 187: 643-653 (1992).
Zhang Et Al. Journal of Virology 65(11): 6101-6110 (1991).
Yanisch-Perron Et Al. Gene 33: 103-119 (1985).
Towbin Et Al. Proc. Natl. Acad. Sci. USA 76(9): 4350-4354 (1979).
Perkus Et Al. Journal of Virology 63(9): 3829-3836 (1989).
Wang Et Al. Gene Therapy 2: 775-783 (1995).
Krougliak Et Al. Human Gene Therapy 6: 1575-1586 (1995).
Sutter Et Al. Journal of Virology 68(7): 4109-4116 (1994).
Dorner Friedrich
Falkner Falko Gunter
Pfleiderer Michael
Scheiflinger Friedrich
Adams Donald E.
Immuno AG.
Parkin Jeffrey S.
LandOfFree
Methods for generating immune responses employing modified vacci does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for generating immune responses employing modified vacci, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for generating immune responses employing modified vacci will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2003765